DiCE Molecules Holding LLC

DiCE Therapeutics, Inc. is a biopharmaceutical company. It designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA.

Eli Lilly

INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

Lilly Completes Acquisition of DICE Therapeutics

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m.

Lilly Announces Extension of Tender Offer to Acquire DICE

AbbVie

Amgen

Horizon Pharma

Pfizer

Seagen

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

On Tuesday, Dice Therapeutics announced a $2.4 billion buyout agreement with Eli Lilly. This deal caused the company's shares to soar.

Why Dice Therapeutics Stock Bolted Higher This Week

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

iShares U.S. Healthcare ETF

Harbor Health Care ETF

Horizon Kinetics Medical ETF

VanEck Vectors Pharmaceutical ETF

Health Care Select Sector SPDR Fund

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a note on Wednesday.  UBS, which has a ‘Buy' rating and a 12-month price target of $498 for Eli Lilly, noted that the acquisition provides two oral IL-17 inhibitors DC-806 and DC-853, as well as additional pipeline opportunities to the company's profile.

Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker

Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.

Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?

DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

On Tuesday, the nearly 150-year pharmaceutical giant announced an agreement to acquire San Francisco-based immunology specialist DICE Therapeutics. Under the terms of the deal, Lilly will pay $48.00 per share in cash for all outstanding DICE shares, a 42% premium to the small cap's Friday close.

Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover

Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.

Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know

Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice Therapeutics Inc. ( DICE , Financial) in a deal valued at $2.4 billion.

Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement

Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.

Eli Lilly Buys DICE Therapeutics for $2.4 Billion

Lilly is paying a 40% premium for Dice's shares. Dice is a clinical-stage biotech with six programs in its pipeline.

Why Shares of Dice Therapeutics Are Skyrocketing Tuesday

Biotech stocks to watch in the stock market now.

2 Biotech Stocks For Your June 2023 Watchlist

MILWAUKEE , June 20, 2023 /PRNewswire/ -- Ademi LLP is investigating DICE (NASDAQ: DICE) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly and Company.  Click here to learn how to join the action https://www.ademilaw.com/case/dice-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether DICE Therapeutics, Inc. has obtained a Fair Price in its transaction with Eli Lilly and Company

Dice Therapeutics Inc (NASDAQ:DICE) was last seen up 37.6% to trade at a fresh all-time high of $46.56, after  Eli Lilly (LLY) revealed it will buy the immunology drug maker for roughly $2.4 billion , or $48 per share, in an all-cash deal that is a 40% premium to DICE's last close.

Options Traders Blast Dice Therapeutics Stock After Buyout

Dice Therapeutics Inc (NASDAQ: DICE) opened more than 35% up this morning after Eli Lilly & Co (NYSE: LLY) said it will buy the immunology company for $2.4 billion.

Eli Lilly is buying Dice Therapeutics for $2.4 billion

Dice Therapeutics (NASDAQ: DICE ) stock is surging higher on Tuesday after Eli Lilly (NYSE: LLY ) announced plans to acquire the biopharmaceutical company. According to a news release, Eli Lilly is paying $48 per share to acquire all outstanding shares of DICE stock through a tender offer.

Why Is Dice Therapeutics (DICE) Stock Up 38% Today?

Dice stock skyrocketed Monday after Eli Lilly pledged to buy the immunology-focused biotech company for $2.4 billion.

Dice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly Buyout

Eli Lilly and Co (NYSE:LLY) said it has signed a definitive agreement to acquire DICE Therapeutics for $2.4 billion, sending shares of the biopharmaceutical company higher in pre-market trade. Under the deal, which has been approved by the boards of both companies, Lilly said it will commence a tender offer to acquire all outstanding shares of DICE for $48 per share in cash, a 42% premium to its previous closing price.

Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover

Sanofi

Markets eased lower in premarket trading to open the week Tuesday morning. Dice Therapeutics received an acquisition bid from Eli Lilly.

2 Biopharma Stocks Making Big Moves Tuesday

Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.

Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DICE Therapeutics, Inc. (NASDAQ: DICE) to Eli Lilly and Company for $48.00 per share in cash is fair to DICE shareholders. Halper Sadeh encourages DICE shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether DICE and i.

News for DiCE Molecules Holding LLC Stock (DICE)